Safusidenib (AB-218, DS-1001)
J201 Phase 2
Nuvation Bio · Phase 2 · Active, not recruiting · Enrollment 25
| Arm | Population | Dose | Estimand | Comparator | Efficacy |
|---|---|---|---|---|---|
| Safusidenib 250 mg BID | IDH1-mutant grade 2 glioma, Japan (n = 27 per company; registry n = 25) | 250 mg | Single arm | n/r | confirmed objective response rate: 51.9%, median follow-up 38.8 months36-month PFS rate: 79.1%, median follow-up 38.8 months |